Tracking Agouron
Executive Summary
Despite growing sales of {Viracept}, Agouron's stock is in the doldrums. It needs a follow-on product, but doesn't have any great near-term prospects of its own and can't spend the research funds necessary to develop earlier ones without hurting earnings. Agouron is therefore turning to licensing later-stage drugs and simultaneously remaking its share structure with tracking stocks. Its idea is to sequester R&D spending into a separately traded cancer company and thereby spare the income statement of Agouron-Viracept.
You may also be interested in...
Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Cosmetic And Personal Care Trademark Review 19 January, 2021
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
CMS Extends National Medicare Coverage For Transcatheter Mitral Valve Repair
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.
Need a specific report? 1000+ reports available
Buy Reports